Protalix presents PRX-115 Phase 2 gout trial update, expects top-line data in second half of 2027
PLX•Protalix BioTherapeutics is enrolling patients in its Phase 2 RELEASE trial of PRX-115 for uncontrolled gout and expects top-line results in the second half of 2027. Revenue for the first nine months of 2026 was $75.6 million, and net income was $26.1 million.
1. Trial and financial update
Protalix BioTherapeutics is enrolling patients in its Phase 2 RELEASE trial of PRX-115 for uncontrolled gout, with top-line results expected in the second half of 2027. Revenue for the first nine months of 2026 rose to $75.6 million from $43.6 million a year earlier, while net income totaled $26.1 million. Cash was $48.5 million as of September 30, 2026, with no debt or warrants. The company also received a $25 million regulatory milestone payment from Chiesi following expanded Elfabrio dosing options in markets including the EU and UK.
